Company intelligence / Profile preview

NCSRT

Apex, North Carolina, USA

Ownership: Private
Development stage: Other

Overview

NCSRT is a bioprocessing technology company that provides advanced filtration and separation solutions for the life sciences industry. The company's core offering is the SmartFlow tangential flow filtration (TFF) platform, which is designed to improve the efficiency and scalability of downstream processing for biologics. Their technology is widely utilized in the production of vaccines, monoclonal antibodies, and recombinant proteins to enhance yield and purity. NCSRT was acquired by Sartorius Stedim Biotech in 2015, integrating its specialized filtration capabilities into Sartorius's broader biomanufacturing portfolio. The company's systems are known for their unique flow path design that minimizes fouling and maximizes throughput.

Modalities: Monoclonal antibodyVaccineRecombinant proteinCell therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on NCSRT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCSRT.

Explore the full profile